Search

Displaying results 3461 - 3470 of 6951 in total
  1. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

  2. Drug

    Diamorphine

    go.drugbank.com/drugs/DB01452
    ApprovedIllicit

    Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United...

  3. Target

    Maltoporin

    go.drugbank.com/bio_entities/BE0003212
    TargetTransporterEscherichia coli (strain K12)

    Also acts as a receptor for several bacteriophages including lambda (PubMed:4201774). Binds maltosaccharides; when LamB binds starch in soft agar, it inhibits motility (PubMed:2832377).

    Synonyms: Lambda receptor protein, Phage lambda receptor protein
  4. Drug

    Telbivudine

    go.drugbank.com/drugs/DB01265
    ApprovedWithdrawn

    Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas.

  6. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.

  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  8. Drug

    Pivampicillin

    go.drugbank.com/drugs/DB01604
    ApprovedWithdrawn

    Pivalate ester analog of ampicillin.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

  10. Drug

    Streptococcus pneumoniae type 2 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10320
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.